NxStage (NASDAQ:NXTM) – Stock analysts at Jefferies Group issued their Q2 2018 earnings per share (EPS) estimates for NxStage in a note issued to investors on Thursday, May 17th. Jefferies Group analyst R. Denhoy forecasts that the medical device company will post earnings per share of ($0.04) for the quarter. Jefferies Group also issued estimates for NxStage’s Q3 2018 earnings at ($0.04) EPS and Q4 2018 earnings at ($0.01) EPS.
Several other research firms also recently weighed in on NXTM. ValuEngine downgraded NxStage from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. BidaskClub raised NxStage from a “strong sell” rating to a “sell” rating in a report on Saturday, March 24th. Finally, Zacks Investment Research downgraded NxStage from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 15th. One investment analyst has rated the stock with a sell rating and ten have assigned a hold rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $30.71.
NxStage opened at $27.04 on Monday, according to MarketBeat Ratings. NxStage has a twelve month low of $21.30 and a twelve month high of $29.93. The firm has a market cap of $1.76 billion, a P/E ratio of -122.91 and a beta of -0.02.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NXTM. Bank of Montreal Can raised its position in NxStage by 15.5% during the 4th quarter. Bank of Montreal Can now owns 572,868 shares of the medical device company’s stock worth $13,880,000 after purchasing an additional 77,082 shares during the last quarter. Renaissance Technologies LLC bought a new position in NxStage during the 4th quarter worth $3,390,000. K2 Principal Fund L.P. bought a new position in NxStage during the 4th quarter worth $4,921,000. Dumac Inc. raised its position in NxStage by 65.0% during the 4th quarter. Dumac Inc. now owns 50,000 shares of the medical device company’s stock worth $1,212,000 after purchasing an additional 19,700 shares during the last quarter. Finally, FNY Partners Fund LP bought a new position in NxStage during the 4th quarter worth $300,000. 82.46% of the stock is currently owned by institutional investors.
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Receive News & Ratings for NxStage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage and related companies with MarketBeat.com's FREE daily email newsletter.